Top in allergy/asthma: Epinephrine autoinjectors lack benefits; rhinitis and mental health
Click Here to Manage Email Alerts
Epinephrine autoinjectors may have limited effectiveness in helping patients survive anaphylaxis events, according to a review published in Clinical and Experimental Allergy.
Healio spoke with Robert J. Boyle, MBChB, PhD, from the National Heart and Lung Institute, Imperial College London concerning the review of various randomized controlled human and animal trials.
The researchers found that varying epinephrine absorption through the muscle and the short-lived effects of the modest dose contained in autoinjectors may inhibit epinephrine autoinjectors from successfully preventing fatal anaphylaxis.
“When discussing epinephrine autoinjectors, doctors should be honest with their patients by acknowledging that these are unlikely to save lives, although a small beneficial effect cannot be excluded,” Boyle told Healio.
It was the top story in allergy/asthma last week.
In another top story, researchers found that poor control of allergic rhinitis was linked to increased symptoms of depression and anxiety among patients in Florida, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Read these and more top stories in allergy/asthma below:
Q&A: Epinephrine autoinjectors may not be adequate in preventing fatal anaphylaxis
Epinephrine autoinjectors may be associated with short-lived peak plasma levels, unpredictable cardiovascular responses as well as varying epinephrine absorption, according to a review published in Clinical and Experimental Allergy. Read more.
Poor allergic rhinitis control may worsen mental health symptoms
Poor allergic rhinitis control was associated with an increase of depressive and anxiety symptoms, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Read more.
As-needed albuterol-budesonide reduces risk for severe asthma exacerbations
Patients with mild asthma lowered their severe exacerbation risk by almost half using as-needed albuterol-budesonide, data presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting suggested. Read more.
Q&A: Video series educates physicians about primary immunodeficiencies
Patients with primary immunodeficiencies experience an average of 9 to 15 years between the onset of their symptoms to diagnosis of their disorder and treatment that could save their lives, according to the Immune Deficiency Foundation. Read more.
Study finds EMS anaphylaxis protocols outdated, incomplete
Anaphylaxis protocols in emergency medical services have outdated recommendations and guidelines, results presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting showed. Read more.